Loading
Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.
Fabrice André is Director of Research at Gustave Roussy and Professor of Medical Oncology at Paris-Saclay, and served as President of the European Society for Medical Oncology (ESMO) for 2025-2026. His specialisms are breast cancer, precision oncology and genomics-driven trials, using comprehensive genomic profiling. He leads the breast cancer genomics programme at Gustave Roussy and was principal investigator of SOLAR-1, the trial of alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer reported in the New England Journal of Medicine. He also led the SAFIR01 and SAFIR02 genomics-guided trials, with the Nature paper on SAFIR02-BREAST testing genomics to select treatment for metastatic breast cancer. His Gustave Roussy profile and PubMed listing are linked.
Re-biopsy and re-sequencing at relapse can find repair defects and a higher mutation burden that the primary did not show, which matters for PARP inhibitor and immunotherapy eligibility in metastatic TNBC.
TILs are prognostic without chemotherapy, which is what a de-escalation biomarker has to show before trials omit treatment on its basis.
Shares Alpelisib, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy, European Society for Medical Oncology (ESMO), HR-positive / HER2-negative breast cancer.
Shares Alpelisib, HR-positive / HER2-negative breast cancer.
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares Alpelisib, HR-positive / HER2-negative breast cancer.
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy, HR-positive / HER2-negative breast cancer.